2b77

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="2b77" size="450" color="white" frame="true" align="right" spinBox="true" caption="2b77, resolution 1.70&Aring;" /> '''Human transthyretin...)
Line 1: Line 1:
-
[[Image:2b77.gif|left|200px]]<br />
+
[[Image:2b77.gif|left|200px]]<br /><applet load="2b77" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="2b77" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="2b77, resolution 1.70&Aring;" />
caption="2b77, resolution 1.70&Aring;" />
'''Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID'''<br />
'''Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID'''<br />
==Overview==
==Overview==
-
Analogues of diflunisal, an FDA-approved nonsteroidal antiinflammatory, drug (NSAID), were synthesized and evaluated as inhibitors of, transthyretin (TTR) aggregation, including amyloid fibril formation. High, inhibitory activity was observed for 26 of the compounds. Of those, eight, exhibited excellent binding selectivity for TTR in human plasma (binding, stoichiometry &gt;0.50, with a theoretical maximum of 2.0 inhibitors bound, per TTR tetramer). Biophysical studies reveal that these eight inhibitors, dramatically slow tetramer dissociation (the rate-determining step of, amyloidogenesis) over a duration of 168 h. This appears to be achieved, through ground-state stabilization, which raises the kinetic barrier for, tetramer dissociation. Kinetic stabilization of WT TTR by these eight, inhibitors is further substantiated by the decreasing rate of amyloid, fibril formation as a function of increasing inhibitor concentration (pH, 4.4). X-ray cocrystal structures of the TTR.18(2) and TTR.20(2) complexes, reveal that 18 and 20 bind in opposite orientations in the TTR binding, site. Moving the fluorines from the meta positions in 18 to the ortho, positions in 20 reverses the binding orientation, allowing the hydrophilic, aromatic ring of 20 to orient in the outer binding pocket where the, carboxylate engages in favorable electrostatic interactions with the, epsilon-ammonium groups of Lys 15 and 15'. The hydrophilic aryl ring of 18, occupies the inner binding pocket, with the carboxylate positioned to, hydrogen bond to the serine 117 and 117' residues. Diflunisal itself, appears to occupy both orientations based on the electron density in the, TTR.1(2) structure. Structure-activity relationships reveal that, para-carboxylate substitution on the hydrophilic ring and dihalogen, substitution on the hydrophobic ring afford the most active TTR amyloid, inhibitors.
+
Analogues of diflunisal, an FDA-approved nonsteroidal antiinflammatory drug (NSAID), were synthesized and evaluated as inhibitors of transthyretin (TTR) aggregation, including amyloid fibril formation. High inhibitory activity was observed for 26 of the compounds. Of those, eight exhibited excellent binding selectivity for TTR in human plasma (binding stoichiometry &gt;0.50, with a theoretical maximum of 2.0 inhibitors bound per TTR tetramer). Biophysical studies reveal that these eight inhibitors dramatically slow tetramer dissociation (the rate-determining step of amyloidogenesis) over a duration of 168 h. This appears to be achieved through ground-state stabilization, which raises the kinetic barrier for tetramer dissociation. Kinetic stabilization of WT TTR by these eight inhibitors is further substantiated by the decreasing rate of amyloid fibril formation as a function of increasing inhibitor concentration (pH 4.4). X-ray cocrystal structures of the TTR.18(2) and TTR.20(2) complexes reveal that 18 and 20 bind in opposite orientations in the TTR binding site. Moving the fluorines from the meta positions in 18 to the ortho positions in 20 reverses the binding orientation, allowing the hydrophilic aromatic ring of 20 to orient in the outer binding pocket where the carboxylate engages in favorable electrostatic interactions with the epsilon-ammonium groups of Lys 15 and 15'. The hydrophilic aryl ring of 18 occupies the inner binding pocket, with the carboxylate positioned to hydrogen bond to the serine 117 and 117' residues. Diflunisal itself appears to occupy both orientations based on the electron density in the TTR.1(2) structure. Structure-activity relationships reveal that para-carboxylate substitution on the hydrophilic ring and dihalogen substitution on the hydrophobic ring afford the most active TTR amyloid inhibitors.
==Disease==
==Disease==
Line 11: Line 10:
==About this Structure==
==About this Structure==
-
2B77 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with 3CA as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2B77 OCA].
+
2B77 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=3CA:'>3CA</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2B77 OCA].
==Reference==
==Reference==
Line 17: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Kelly, J.W.]]
+
[[Category: Kelly, J W.]]
-
[[Category: Palaninathan, S.K.]]
+
[[Category: Palaninathan, S K.]]
-
[[Category: Sacchettini, J.C.]]
+
[[Category: Sacchettini, J C.]]
[[Category: 3CA]]
[[Category: 3CA]]
[[Category: amyloid]]
[[Category: amyloid]]
Line 25: Line 24:
[[Category: ttr]]
[[Category: ttr]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 20:59:19 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:34:48 2008''

Revision as of 14:34, 21 February 2008


2b77, resolution 1.70Å

Drag the structure with the mouse to rotate

Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID

Contents

Overview

Analogues of diflunisal, an FDA-approved nonsteroidal antiinflammatory drug (NSAID), were synthesized and evaluated as inhibitors of transthyretin (TTR) aggregation, including amyloid fibril formation. High inhibitory activity was observed for 26 of the compounds. Of those, eight exhibited excellent binding selectivity for TTR in human plasma (binding stoichiometry >0.50, with a theoretical maximum of 2.0 inhibitors bound per TTR tetramer). Biophysical studies reveal that these eight inhibitors dramatically slow tetramer dissociation (the rate-determining step of amyloidogenesis) over a duration of 168 h. This appears to be achieved through ground-state stabilization, which raises the kinetic barrier for tetramer dissociation. Kinetic stabilization of WT TTR by these eight inhibitors is further substantiated by the decreasing rate of amyloid fibril formation as a function of increasing inhibitor concentration (pH 4.4). X-ray cocrystal structures of the TTR.18(2) and TTR.20(2) complexes reveal that 18 and 20 bind in opposite orientations in the TTR binding site. Moving the fluorines from the meta positions in 18 to the ortho positions in 20 reverses the binding orientation, allowing the hydrophilic aromatic ring of 20 to orient in the outer binding pocket where the carboxylate engages in favorable electrostatic interactions with the epsilon-ammonium groups of Lys 15 and 15'. The hydrophilic aryl ring of 18 occupies the inner binding pocket, with the carboxylate positioned to hydrogen bond to the serine 117 and 117' residues. Diflunisal itself appears to occupy both orientations based on the electron density in the TTR.1(2) structure. Structure-activity relationships reveal that para-carboxylate substitution on the hydrophilic ring and dihalogen substitution on the hydrophobic ring afford the most active TTR amyloid inhibitors.

Disease

Known diseases associated with this structure: Amyloid neuropathy, familial, several allelic types OMIM:[176300], Amyloidosis, senile systemic OMIM:[176300], Carpal tunnel syndrome, familial OMIM:[176300], Dystransthyretinemic hyperthyroxinemia OMIM:[176300]

About this Structure

2B77 is a Single protein structure of sequence from Homo sapiens with as ligand. Full crystallographic information is available from OCA.

Reference

Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis., Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW, J Med Chem. 2004 Jan 15;47(2):355-74. PMID:14711308

Page seeded by OCA on Thu Feb 21 16:34:48 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools